Biosotop 鼎邦生物
中文/EN

TECHNOLOGY & PRODUCTS

Building an MR metabolic imaging product platform with deuterated molecular probes

Using ²H spectroscopic imaging to detect the distribution and flux of glucose and downstream metabolites in real time, providing quantifiable metabolic evidence for clinical care and drug development.

Technology Platform

Exogenous stable-isotope probes take metabolic analysis from static observation to full-process quantification

MR metabolic imaging falls into two categories: endogenous nuclides and exogenous molecular probes. Biosotop focuses on stable-isotope probes such as ²H and ¹⁷O, observing the full metabolic process and analyzing pathway flux.

Endogenous Nuclides (Label-Free)

  • ¹H MRS: observes static metabolites such as NAA, choline, creatine and GABA.
  • CEST: observes chemical-exchange signals such as -NH, -NH₂ and -OH.
  • ³¹P / ²³Na: provides functional information such as phosphorus spectroscopy and sodium imaging.
  • Detects steady-state metabolite concentrations for early disease diagnosis.

Exogenous Molecular Probes (Isotopically Labeled)

  • ²H: deuterium-labeled probes such as glucose, fatty acids and fumarate.
  • ¹³C: research probes such as carbon-13 pyruvate, urate and fumarate.
  • ¹⁷O: oxygen-17 gas for oxygen-metabolism and mitochondrial-function detection.
  • Detects dynamic changes in metabolic pathways and flux in real time, for metabolic typing of disease and treatment assessment.

Product Pipeline

From a commercialized tracer to multi-category metabolic probes

In production & commercialized

BST001 Deuterated Glucose Tracer

The world's first deuterated glucose molecular tracer to enter the IND registration path, used for MR metabolic imaging.

  • R&D started in 2020, achieving kilogram-scale production
  • Pre-IND application submitted on March 16, 2026
  • Clinical trial approval expected in September 2026
In development

Deuterated Fatty Acid / Amino Acid Imaging Agents

A portfolio of molecular imaging agents for hepatic lipid metabolism, tumor metabolism and multi-pathway mechanism research.

  • Expanding multiple deuterated probes such as fatty acids and amino acids
  • Serving the research ecosystem and clinical indication expansion
  • Building a richer product pipeline
Planned

¹⁷O-Oxygen (¹⁷O-O₂)

Directly probing mitochondrial function to provide metabolic-function evidence for disease mechanism research and drug development.

  • Targeting mitochondrial function assessment
  • Completing the oxygen-metabolism product matrix
  • Synergizing with multi-nuclear MR equipment upgrades